Interview with Silvio Gherardi, President, Baxter Italy
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Address: Piazzale dell’Industria, 20
00144 Roma
Tel: (+39) 06 32491-1
Web: http://www.baxteritalia.it/
Baxter has been present in Italy since 1969, when the Company under the name of Travenol Laboratories Ireland, entered the market in our country of some of its medicines for infusions and kidney.Two years later, in 1971, the company acquired Sesto Fiorentino, which still represents a standard of excellence in the production of preparations ready for use in parenteral nutrition and chemotherapy .
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini…
Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC…
Some of the biggest pharma and healthcare stories coming out of Italy, including Italy’s antitrust investigation of Novartis and Genentech; Johnson & Johnson’s EUR 125 million investment in its Italian…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
See our Cookie Privacy Policy Here
